wiki:Research/DesignStudy/SteeringGroup/2020-09-24

LhARA Steering Group meeting #4

24th September 2020 10:00 GMT

Notes

  1. Notes of last meeting and actions arising:
    • KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
      • Superceded.
    • KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
      • Ongoing.
    • KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
      • Ongoing.
    • KL: Ensure one representative per group at the next LhARA SG meeting.
      • Stands.
    • KL: Raise NIHR engagement with K.Gleeson.
      • Done.
    • KL: Seek PPI representative for SG.
      • Done. Welcome G. Jones and H. Hall.
    • KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
      • StG: Brm is not a radiotherapy research centre. Shoudl contact Manchester, Oxford, and Liverpool.
      • TG: Also need to contact with relevant medical physics groups.
    • KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
      • Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
    • KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
      • Ongoing.
    • KL: Write to J.Clarke to ask for support to reach out to relevant industry.
      • Stands.
    • PA: Make contact with MTC to see how to make contact with relevant industry.
      • Stands
    • PA/KL will cooperate in drafting a letter.
      • Stands.
    • KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
      • Stands.
    • KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
      • Done. Meeting organised between A.Price and R.McLauchlan a success.
  1. Update on progress: KL
  1. Towards a PPI strategy for LhARA: GJ, HH
    • Main stem of strategy is to raise awareness with public and with patients. Then develop the engagement as the programme progresses.
    • Hard to see anything which would not benefit patients and also the health services. Patient input is vital all at all stages in the development of the programme.
    • Management of PPI will take time. Perhaps means that we need to include some resource. Marsden PPI outreach.
    • HH sits on various PPI advisory groups and can make links top various institutes.
      • Focus on engagement rather than involvement.
    • StG:
      • Agrees re effort involved in getting broad activity. Link to the Royal Marsden will be important.
    • KK:
      • BRC links important.
    • SG expressed it grateful recognition of the efforts of GJ and HH and the PPI representatives in drafting the two Lay Summaries so far. Both are/will be published.
  1. Towards a clinician-engagement strategy for LhARA: StG
    • Neil Burnett and Adrian Crellin from Brm meeting might be pursuared to promote activity. Elizabeth Schuster, Rostoc is a researcher into the impact of microbeams.
    • There is a need to reach out to research-active clinicians. Probably should build up a target list in preparation for a webinar. A process such as that adopted by TP for the endstation/diagnostics development would be appropriate.
    • KK:
      • Noted the perception in the community that laser-ion beams are like nuclear fusion -- always 15 years away.
      • Critical to develop clear statement of what what the laser-hybrid technique can do that others cant.
    • Meeting:
      • We agreed to work towards a meeting of the relevant peer groups. TKW agreed to make contact with IoP at "top level".
  1. Transformative Healthcare Technologies second call: KL/All
    Updated outline presented at the LhARA weekly meeting 22Sep20
    Discussion included:
    • PPI: GJ/HH
    • Clinician engagement: StG
    • Plan for preparation of proposal
      • Scope
      • Work packages
      • Stakeholders

  1. DONMs
    • TBD
  1. AoB

Agenda

  1. Notes of last meeting and actions arising:
    • KL: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
      • Superceded.
    • KL/CB: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
      • Ongoing.
    • KL/KK: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
      • Ongoing.
    • KL: Ensure one representative per group at the next LhARA SG meeting.
      • Stands.
    • KL: Raise NIHR engagement with K.Gleeson.
      • Done.
    • KL: Seek PPI representative for SG.
      • Done. Welcome G. Jones and H. Hall.
    • KK, JPar, CW, KL: Make relevant contact with local PPI groups as described in item 4.
    • KL&JPar: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
      • Done. Letter written and sent, see under clinician engagement below. Revised action needs to be agreed.
    • KK, JPar, CW, KL, SG: Make relevant contact with local clinician groups as described in item 4.
      • Ongoing.
    • KL: Write to J.Clarke to ask for support to reach out to relevant industry.
      • Stands.
    • PA: Make contact with MTC to see how to make contact with relevant industry. PA/KL will cooperate in drafting a letter.
    • KL: Review proposed w/p structure and skills matrix taking into account comments under item 4.
      • Stands.&&
    • KL/RMcL: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
      • Done. Meeting organised between A.Price and R.McLauchlan a success.
  1. Update on progress: KL
  1. Towards a PPI strategy for LhARA: GJ, HH
  1. Towards a clinician-engagement strategy for LhARA: StG
  1. Transformative Healthcare Technologies second call: KL/All
    Updated outline presented at the LhARA weekly meeting 22Sep20
    Discussion to include:
    • PPI
    • Clinician engagement:
    • Industrial engagement:
    • Plan for preparation of proposal
      • Scope
      • Work packages
      • Stakeholders
    • Next steps discussion

  1. DONMs
    • TBD
  1. AoB


Last modified 19 months ago Last modified on Nov 23, 2020 9:55:50 AM

Attachments (4)

Download all attachments as: .zip